Unlike the Venture-Capital model, our site is not just a display ad with great graphics and not much else except a vague mission statement. Our site is dense with information, such as clinical trial results, references to the scientific literature, etc.
Santa Fe, NM (PRWEB) April 12, 2006 —-
Since becoming a publicly traded company, big changes are taking place at CytoDyn, Inc. In order to benefit their investors, shareholders, and anyone interested in AIDS/HIV treatments, CytoDyn is pleased to announce the unveiling of their redesigned website. The company also began restructuring its Board of Directors in January and they hope both of these renovations will provide an abundance of information for those who are interested in the focuses of the company.
It is important to note, though, that CytoDyn’s website contains forward looking statements that are not historical facts. These claims are estimates based upon current information and involve a number of risks and uncertainties. There can be no assurance that such risks and uncertainties, amongst other factors, will not affect the accuracy of such forward looking statements. It is impossible to identify all factors that could cause actual results to differ materially by those estimated by CytoDyn, Inc. That being said, reelected Chairman of the Board and CEO Allen D. Allen comments on the highlights of the newer model, “Unlike the Venture-Capital model, our site is not just a display ad with great graphics and not much else except a vague mission statement. Our site is dense with information, such as clinical trial results, references to the scientific literature, etc.” Mr. Allen is also responsible for the company’s newly refurbished website. The information offered is updated regularly by him personally.
CytoDyn, Inc. is best known for its contribution of Cytolin to the developing sciences of HIV treatments. This pioneering AIDS drug was discovered by Mr. Allen over a decade ago. Cytolin is an immune therapy that has seen encouraging results for people receiving HIV treatments through Phase I(b)/II(a) in private studies. This AIDS drug targets the person’s immune system and not the HIV virus. This variable ensures that the virus does not mutate to be unaffected by the drug. This is a common problem today with antibiotics. The survival of the fittest game is championed by viruses, leaving common antibiotics useless. The innovation of Cytolin is that it targets the immune system and not the virus, meaning the therapy is not affected by virus mutations.
CytoDyn’s AIDS drugs are also being developed for Chinese distribution, by way of CytoDyn’s joint venture with Timeway International. CytoDyn’s HIV/AIDS treatments will become available along with other pharmaceutical biotechnology contributed by non-competing U.S. biotech firms. This collaboration hopes to offset the estimate figured by UNAIS and other organizations that between 10 and 20 million Chinese could be infected with the HIV/AIDS virus by 2010.
About CytoDyn, Inc.:
CytoDyn, Inc. is a publicly traded company (ticker symbol OTCBB: CYDY.) Allen D. Allen is Chairman, CEO, and the discoverer of CytoDyn’s AIDS drug, Cytolin.
# # #